In a historic milestone for neurotechnology, Coherence Neuro—a San Francisco-based longevity startup with close ties to Elon Musk’s Neuralink—has commenced human testing of a specialized brain implant designed to detect and disrupt cancer.
The targeted therapy, marketed as Elahere, has shown improved survival rates and better quality of life in women with advanced ovarian cancer that no longer responds to platinum-based chemotherapy.
